CNN writer Jacqueline Howard reports that a recent clinical trial reveals that Janssen’s canagliflozin lowers the risk of kidney failure. Diabetes influences kidney failure worldwide. Partially reported in the New England Journal of Medicine, the recent study evidenced that the risk of kidney failure and cardiovascular-related problems was reduced in patients with type 2 diabetes and kidney disease who took canagliflozin. Janssen (a subsidiary of Johnson and Johnson) financed the study. Follow the CNN article in the link below.